Alpha 2.0
Login Register
» Authors » Claudia Murta de Oliveira

Claudia Murta de Oliveira

Explore the profile of Claudia Murta de Oliveira including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 215
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pediatrics
Top 10 Co-Authors
Johann Motsch
Eun Ju Choo
Joan R Butterton
Angela Aggrey
Viktor Stus
Anthony L Cunningham
Marc Dionne
John Pullman
Flavie Moreau
Carol Pretswell
Published In
Clin Infect Dis
Lancet Infect Dis
Clin Transl Sci
J Pediatric Infect Dis Soc
Affiliations
Soon will be listed here.
Recent Articles
1.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
Okhuysen P, Ramesh M, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira C, et al.
Clin Infect Dis . 2024 Feb; 78(6):1462-1472. PMID: 38305378
Background: Exposure to antibiotics predisposes to dysbiosis and Clostridioides difficile infection (CDI) that can be severe, recurrent (rCDI), and life-threatening. Nonselective drugs that treat CDI and perpetuate dysbiosis are associated...
2.
Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase II randomized trial
McKinnon J, Santiaguel J, de Oliveira C, Yu D, Khursheed M, Moreau F, et al.
Clin Transl Sci . 2023 Oct; 16(12):2640-2653. PMID: 37873555
Enpatoran is a selective inhibitor of toll-like receptors 7 and 8 (TLR7/8) that potentially targets pro-inflammatory pathways induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A phase II study...
3.
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)
Sferra T, Merta T, Neely M, de Oliveira C, Lassaletta A, Fortuny Guasch C, et al.
J Pediatric Infect Dis Soc . 2023 Jun; 12(6):334-341. PMID: 37389891
Background: Therapies to prevent recurrence of Clostridioides difficile infection (CDI) in pediatric patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for prevention of recurrent CDI in adults....
4.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Boutry C, Hastie A, Diez-Domingo J, Tinoco J, Yu C, Andrews C, et al.
Clin Infect Dis . 2021 Jul; 74(8):1459-1467. PMID: 34283213
Background: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV)...
5.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Motsch J, de Oliveira C, Stus V, Koksal I, Lyulko O, Boucher H, et al.
Clin Infect Dis . 2019 Aug; 70(9):1799-1808. PMID: 31400759
Background: The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. Methods: Randomized, controlled, double-blind, phase 3 trial. Hospitalized patients with...
6.
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials
Gerding D, Cornely O, Grill S, Kracker H, Marrast A, Nord C, et al.
Lancet Infect Dis . 2019 Feb; 19(3):265-274. PMID: 30709665
Background: Cadazolid is a novel quinoxolidinone antibiotic developed for treating Clostridium difficile infection. We aimed to investigate the safety and efficacy of cadazolid compared with vancomycin in patients with C...